Task Order 3: Interventional Agent Development Services Program

任务顺序 3：介入药物开发服务计划

• 批准号: 10704968
• 负责人: Jon Carl Mirsalis
• 金额: $ 1.17万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-17 至 2019-04-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10704968
• 关键词: Categories; Chemistry; Communicable Diseases; Contracts; Hypersensitivity skin testing; Image; Interventional Agent Development; National Institute of Allergy and Infectious Disease; Services; Toxin; in-vivo diagnostics; pathogen; pre-clinical; preclinical development; programs; reagent testing; service programs; therapeutic development

The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins, such as imaging and skin test reagents. This contract provides for chemistry and manufacturing services under the NIAID Preclinical Services for the Development of Interventional Agents Program.

介入制剂开发服务计划提供服务，以促进针对引起传染病的病原体和/或毒素的治疗方法和新的体内诊断方法的临床前开发，例如成像和皮肤测试试剂。该合同提供 NIAID 介入药物开发临床前服务项目下的化学和制造服务。